Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Squamous Cell

Explore clinical trials studying Neoplasms, Squamous Cell. Study availability and eligibility vary by location and protocol.

815 public trials 208 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Squamous Cell trial results

Completed

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

NCT00042679

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +15 more
Locations
  • Bakersfield, California, United States
  • Berkeley, California, United States
  • Torrance, California, United States
  • Miami Beach, Florida, United States
View Trial Details
Active, Not Recruiting

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983

Conditions
Adnexal Diseases, Advanced or Metastatic Solid Tumors, Breast Diseases, +64 more
Locations
  • Massachusetts General Hospital - Boston Boston, Massachusetts, United States
  • John Theurer Cancer Center Hackensack, New Jersey, United States
  • Mount Sinai Tisch Cancer Center New York, United States
  • NEXT Oncology - Dallas Dallas, Texas, United States
View Trial Details
Active, Not Recruiting

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

NCT04543617

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
Locations
  • Florida Cancer Specialists - Fort Myers (Broadway) Fort Myers, Florida, United States
  • Cancer Center of Kansas Wichita, Kansas, United States
  • Great Lakes Cancer Center Williamsville, New York, United States
  • Instituto de Investigaciones Metabolicas (Idim) Buenos Aires, Argentina
View all 167 locations
View Trial Details
Active, Not Recruiting

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

NCT05078047

Conditions
Adenocarcinoma, Basal Cell Carcinoma, Breast Diseases, +69 more
Locations
  • Institut de cancérologie de l'Ouest Angers, France
  • Clinique Sainte Catherine Avignon, France
  • Centre Hospitalier de la Côte Basque Bayonne, France
  • CHU Bordeaux - Hôpial Saint André Bordeaux, France
View all 33 locations
View Trial Details

Related conditions